Table 16.
Effect of AVN-101 on cardio-vascular parameters of dogs (beagle)
| AVN-101 dose, mg/kg | 0.05 | 0.5 | 2 | 10 |
| Blood plasma concentration, μM | 0.14 ± 0.02 | 0.99 ± 0.04 | 3.28 ± 0.30 | 11.1 ± 2.15 |
| femoral SBP | – | down 17 mm Hg, 13% (p < 0.05) | down 21 mm Hg, 16% (p < 0.05) | down 15 mm Hg,11% (p > 0.05) |
| femoral DBP | – | – | – | down 12 mm Hg,17% (p < 0.05) |
| femoral BF | – | – | – | up 35 ml/min (27%, p < 0.05) |
| aortic SBP | – | – | down 8 mmHg, 8% (p < 0.05) | – |
| aortic DBP | – | – | – | down 9 mmHg, 13% (p < 0.05) |
| left ventricular SBP | – | – | – | up 16 mmHg (16%, p < 0.01) |
| left ventricular DBP | – | – | – | down 2 mmHg (40%, p < 0.05) |
| HR | – | up 28 bpm (39%, p > 0.05) | up 39 bpm, 56% (p < 0.05) | up 118 bpm, 164% (p < 0.001) |
| QT interval | – | – | down 40 ms (p < 0.01) at 30 min | down 80 ms (p < 0.001) at 30 min |
| QTcV interval | – | – | down 24 ms (p < 0.01) at 30 min | down 35 ms (p < 0.001) at 30 min |
SBP, systolic blood pressure; DBP, diastolic blood pressure; BF, blood flow; HR, heart rate.